A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: TORL-5-700
DRUG: TORL-5-700 at MTD/RP2D
DRUG: TORL-5-700 at MTD/RP2D in combination with another agent

Sponsor

TORL Biotherapeutics, LLC